NCT07124013View on ClinicalTrials.gov

A Study of Olomorasib (LY3537982) in Healthy Japanese Participants

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy

Interventions

DRUG

Olomorasib

Administered orally

Trial Locations (1)

813-0017

Souseikai Fukuoka Mirai Hospital, Fukuoka

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY